ARK Genomic Financials
| ARKG Etf | USD 27.28 1.05 4.00% |
Net Expense Ratio 0.0075 | 3 y Sharp Ratio (0.65) |
ARK |
The data published in ARK Genomic's official financial statements typically reflect ARK Genomic's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving ARK Genomic's quantitative information. For example, before you start analyzing numbers published by ARK accountants, it's essential to understand ARK Genomic's liquidity, profitability, and earnings quality within the context of the ARK ETF Trust space in which it operates.
ARK Genomic Etf Summary
ARK Genomic competes with Freedom Day, Franklin Templeton, IShares MSCI, Tidal Trust, and IShares Dividend. The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . Ark Genomic is traded on BATS Exchange in the United States.| Instrument | USA Etf View All |
| Exchange | BATS Exchange |
| ISIN | US00214Q3020 |
| CUSIP | 00214Q302 |
| Region | Global |
| Investment Issuer | ARK |
| Etf Family | ARK ETF Trust |
| Fund Category | Strategy |
| Portfolio Concentration | Theme |
| Benchmark | Dow Jones Industrial |
| Phone | NA |
| Currency | USD - US Dollar |
ARK Genomic Key Financial Ratios
ARK Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ARK Genomic's current stock value. Our valuation model uses many indicators to compare ARK Genomic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ARK Genomic competition to find correlations between indicators driving ARK Genomic's intrinsic value. More Info.ARK Genomic Revolution is the top ETF in price to earning as compared to similar ETFs. It also is the top ETF in price to book as compared to similar ETFs fabricating about 0.08 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for ARK Genomic Revolution is roughly 12.84 . Comparative valuation analysis is a catch-all technique that is used if you cannot value ARK Genomic by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ARK Genomic Revolution Systematic Risk
ARK Genomic's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ARK Genomic volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on ARK Genomic Revolution correlated with the market. If Beta is less than 0 ARK Genomic generally moves in the opposite direction as compared to the market. If ARK Genomic Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ARK Genomic Revolution is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ARK Genomic is generally in the same direction as the market. If Beta > 1 ARK Genomic moves generally in the same direction as, but more than the movement of the benchmark.
About ARK Genomic Financials
What exactly are ARK Genomic Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include ARK Genomic's income statement, its balance sheet, and the statement of cash flows. Potential ARK Genomic investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although ARK Genomic investors may use each financial statement separately, they are all related. The changes in ARK Genomic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ARK Genomic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.ARK Genomic Thematic Clasifications
ARK Genomic Revolution is part of several thematic ideas from Strategy ETFs to Theme ETFs. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasARK Genomic January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ARK Genomic help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ARK Genomic Revolution. We use our internally-developed statistical techniques to arrive at the intrinsic value of ARK Genomic Revolution based on widely used predictive technical indicators. In general, we focus on analyzing ARK Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ARK Genomic's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.98 | |||
| Information Ratio | 0.0617 | |||
| Maximum Drawdown | 12.45 | |||
| Value At Risk | (4.09) | |||
| Potential Upside | 4.88 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARK Genomic Revolution. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.